SCHEMBL12835264

SCHEMBL12835264

Cc1cc(NC(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)O)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
HIF1A Q16665 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.46
KDM4E B2RXH2 2/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
TP53 P04637 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
MAPT P10636 3/20 0.43
PKM P14618 2/20 0.43
ALDH1A1 P00352 2/20 0.42
HSP90AA1 P07900 1/20 0.42
G6PD P11413 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7820662 0.90 CYP1A2 (0.56) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL12172978 0.88 HSD17B10 (0.54) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL7814149 0.86 NPC1 (0.59) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL12835240 0.83 NPC1 (0.46) CYP1A2NPC1RAB9AKDM4EPOLB
SCHEMBL12172975 0.81 RAB9A (0.53) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL12172977 0.81 GRM4 (0.56) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL12835323 0.81 HSD17B10 (0.55) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL12172972 0.80 LMNA (0.52) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL7822944 0.79 MEN1 (0.58) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A
SCHEMBL7819848 0.79 NPC1 (0.62) CYP1A2CYP2C9CYP3A4CYP2D6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031663-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-01-29 US disclosed
US-20150031663-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-01-29 US disclosed
WO-2011026107-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE UNIVERSITY OF NOTRE DAME DU LAC (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031663-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE MPO, ALPI, NQO1 CYP1A2 916/4885CYP2C9 306/4885CYP3A4 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.